Portola caps a problem-plagued year with an application for anticoagulant betrixaban
Portola $PTLA has had an awful year so far in 2016. Its anticoagulant betrixaban failed a pivotal study in March and then the FDA rejected …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
